Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Retina. 2019 Jan;39(1):69–78. doi: 10.1097/IAE.0000000000001909

Figure 2. Baseline and 2-year CST/RNFL of an eye treated with ranibizumab.

Figure 2

Figure 2

Figure A and B shows the cross-sectional B-scan images from a Heidelberg Spectralis OCT 7 line scan with the ETDRS grid map showing the central subfield thickness at baseline and two years. Figure C and D shows the cross-sectional B-scan images, temporal-superior-nasal-inferior-temporal map and a breakdown of the segmental thickness of the RNFL at baseline and two years